The advent of optical coherence tomography (OCT) imaging has changed the way ophthalmologists image the ocular surface and anterior segment of the eye. Its ability to obtain dynamic, high and ultra-high resolution, cross-sectional images of the ocular surface and anterior segment in a noninvasive and rapid manner allows for ease of use. In this review, we focus on the use of anterior segment OCT, which provides an “optical biopsy” or in vivo imaging of various ocular surface and corneal pathologies, allowing the clinician to diagnose diseases otherwise not visualized by traditional methods. The utility of anterior segment OCT for various anterior segment pathologies is reviewed.

Purpose: To compare the efficacy of topical 5-fluorouracil 1% (5FU) and interferon alfa-2b 1 MIU/mL (IFN) eye drops as primary treatment modalities for ocular surface squamous neoplasia (OSSN).Design: Retrospective, comparative, interventional case series.Methods: Fifty-four patients who received 5FU and 48 patients who received IFN as primary therapy for OSSN were included. Primary outcome measures were the frequency of clinical resolution and time to OSSN recurrence by treatment modality. Secondary outcome was the frequency of side effects with each therapy. Results:The mean age of patients was 68 years. More Hispanics were treated with 5FU. In a univariable analysis, frequency of OSSN resolution was higher with 5FU (96.3%, n = 52) than with IFN (81.3%, n = 39), p=0.01. In a multivariable analysis, treatment modality did not remain a significant predictor of resolution. In patients whose OSSN resolved, time to resolution was similar with both agents, (5FU -mean 6.6 months, standard deviation (SD) 4.5 versus IFN -mean 5.5 months, SD 2.9, p = 0.17). Of the 52 eyes whose OSSN resolved with 5FU, 11.5 % of lesions (n=6) recurred while of the 39 eyes whose OSSN resolved with IFN, 5.1% of lesions (n = 2) recurred, p=0.46. Kaplan Meier survival curves of OSSN recurrence were similar between groups (log rank=0.16). One-year recurrence rates were 11.4% with 5FU and 4.5% with IFN. Eyelid edema (p=0.04) and tearing (p=0.02) were more significant with 5FU.

The most frequently encountered non-pigmented tumor of the ocular surface is ocular surface squamous neoplasia (OSSN). Over the past two decades, the pharmacological management of OSSN has grown, with topical 5-fluorouracil, mitomycin, and interferon alpha 2b all being successfully used to treat this disease. Other agents, such as anti-vascular endothelial growth factor (VEGF), retinoic acid, cidofovir and Aloe vera , have less frequently been used in the treatment of OSSN. This review will discuss these pharmacologic agents, summarizing available data and presenting the approach to the treatment of these tumors.

Purpose Individuals receiving botulinum toxin A (BoNT-A) injections in the head and neck for migraine treatment have reported decreases in photophobia and sensations of dryness, independent of ocular surface parameters. We hypothesized that patients without migraine but with similar ocular neuropathic-like symptoms would also experience symptomatic improvement with periocular BoNT-A injections, independent of ocular surface changes. Observations We identified four individuals without a history of migraine but with neuropathic ocular pain (symptoms of dryness, burning, and photophobia that were out of proportion to ocular surface findings and unresponsive to ongoing dry eye (DE) therapies). Individuals underwent 1 session of periocular BoNT-A injections. Validated questionnaires (Visual Light Sensitivity Questionnaire-8, Dry Eye Questionnaire-5) assessed photophobia and DE symptoms pre- and 1-month post-injections. All four reported improvements in frequency and severity of photophobia and eye discomfort following BoNT-A injections. Tear film parameters (phenol red thread test, tear break-up time, corneal staining, and Schirmer test) and eyelid (palpebral fissure height and levator palpebrae superioris function) and eyebrow (position) anatomy were also evaluated before and after injections. Despite a unanimous improvement in symptoms, there were no consistent changes in ocular surface parameters with BoNT-A injections across individuals. Conclusions Periocular BoNT-A shows promise in reducing photophobia and sensations of dryness in individuals with neuropathic-like DE symptoms without a history of migraine, independent of tear film, eyelid, or eyebrow parameters.